The business of developing new medicines and bringing them to market has never been more challenging – and there’s no relief in sight. Indeed, the industry is facing what amounts to a financial superstorm over the next 4-5 years. Between evolving policies in play and growing financial pressures, the possibility…
The traditional pharmaceutical commercial model was built for a market that no longer exists. Greater scrutiny of value, more complex customer relationships, new channels of engagement and mounting pressure on margins are forcing companies to reconsider how they organize, invest and compete. But recognizing the need for change is easier…
The rumored $400 billion merger discussions between AstraZeneca and Bristol Myers Squibb didn’t get very far, but the episode offered another indication of the strategic pressure facing large pharmaceutical companies as they confront patent expirations and an increasingly demanding commercial environment. The question for pharma leaders is no longer simply…
While the reported $400 billion merger discussions between AstraZeneca and Bristol Myers Squibb never advanced, the fact that a combination of this scale was even rumored sent shock waves through the industry. That the deal may have been considered at all reflects the extraordinary strategic pressure now facing large pharmaceutical…
Recent activity in Washington—from the Patients Deserve Price Tags Act now moving through the Senate, to the House Ways and Means Committee hearing with Hospital CEOs in April—illustrates that dissatisfaction with the current state of healthcare delivery continues to grow. While pricing and affordability are the most visible part of…
In its latest annual report, IQVIA showed that the 340B drug pricing program has continued to grow at double digit rates. In 2025, 340B drug sales grew by 20.3% year-over-year reaching $179.5B. If you adjust this data for missing 340B sales, IQVIA projects that the 340B program is “approximately $200B,…
